About Aurigene Pharmaceutical Services Limited
Data last updated:
Aurigene Pharmaceutical Services Limited is a public limited company based in Bangalore, Karnataka, India, a subsidiary of Aurigene Oncology Limited (Formerly, Aurigene Discovery Technologies Limited). It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 16 September 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U74999KA2019PLC127964. Its GSTIN is 29AASCA7299J1ZM (Karnataka). The company holds 2 GST registrations, all of them active.
The company has an authorised share capital of ₹170 Cr and a paid-up capital of ₹156.12 Cr. It is led by directors including Erez Israeli and Deepak Sapra.
Its last annual general meeting (AGM) was held on 16 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 39 – 40 KIADB Industrial Area Electronic City Phase II Hosur Road, Bangalore, Karnataka, India – 560100.
As per the financials filed for FY 2025, the company reported a revenue of ₹644.99 Cr, a growth of 44% compared to the previous year. For the same year it recorded a net profit of ₹64.94 Cr (net margin 10.1%) and EBITDA of ₹184.27 Cr (EBITDA margin 28.6%). Revenue has grown at a compounded annual rate (CAGR) of 21% over three years.
The company has about 906 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Aurigene Pharmaceutical. Court records list 1 case involving the company, including 1 filed by the company; 1 case is pending. The company has 3 deals on record (2 rights issues, 1 debt financing), with disclosed funding of ₹380 Cr; the latest was in May 2024. Its 4 peer companies in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development) are compared by revenue, 2 larger and 2 smaller; the largest is Lambda Therapeutic Research Limited with revenue of ₹831.25 Cr. The company has 6 MSME Form 1 returns on record between 2020 and 2023, listing 8 overdue payments to 2 micro and small suppliers.
For more details, the company can be reached via its website aurigeneservices.com.
Company details
Contact details
Aurigene Pharmaceutical Services Limited's registered office is in Bangalore, Karnataka. Its website is aurigeneservices.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address39 – 40 KIADB Industrial Area Electronic City Phase II Hosur Road, Bangalore, Karnataka, India – 560100
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Aurigene Pharmaceutical Services Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Aurigene Pharmaceutical Services operates one associated brand: Aurigene Pharmaceutical. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provides integrated CRO and CDMO services for drug discovery and manufacturing. | aurigeneservices.com |
Business activity
The main business activity of Aurigene Pharmaceutical Services is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Aurigene Pharmaceutical Services Limited, buy the company report.
Financials of Aurigene Pharmaceutical Services Limited
FY 2025 filings availableAurigene Pharmaceutical Services Limited reported revenue of ₹644.99 Cr (up 44% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 21% over three years, including 44% growth in the latest year. EBITDA rose 111% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹184.27 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹64.94 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 28.6% | ||||
| Net Profit Margin | 10.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Aurigene Pharmaceutical Services Limited, buy the company report.
Board of directors and KMP of Aurigene Pharmaceutical Services Limited
Aurigene Pharmaceutical Services Limited currently reports 4 directors and 2 key managerial personnel. 6 former directors have served the organization.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Erez Israeli Also directs: Dr.Reddy's Laboratories Ltd | Director | 16 Sep 2019 | 7 Years 1 Months | Current |
| Deepak Sapra | Director | 16 Sep 2019 | 7 Years 1 Months | Current |
| Mannam Venkata Narasimham Also directs: Dr.Reddy's Laboratories Ltd, Dr. Reddy's Formulations Limited, DRL Impex Limited and 5 more | Director | 16 Sep 2019 | 7 Years 1 Months | Current |
| Atul Sachdeva Also directs: Kyva Kazoku LLP | Cfo | 27 Jul 2022 | 4 Years 2 Months | Current |
| Sapna | Company Secretary | 14 Nov 2024 | 1 Years 11 Months | Current |
| Jesal Agarwal Also directs: Dr. Reddy's Formulations Limited, Citizen's Electoral Trust, Dres Energy Private Limited and 1 more | Director | 29 Mar 2024 | 2 Years 6 Months | Current |
Peer comparison
Aurigene Pharmaceutical Services Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Lambda Therapeutic Research Limited | ₹831.25 Cr (FY 2025) | 18.0% | Ahmedabad, Gujarat, India | |||
| Icon Clinical Research India Private Limited | ₹816.1 Cr (FY 2025) | 28.0% | Chennai, Tamil Nadu, India | |||
| Aurigene Pharmaceutical Services Limitedthis company | ₹644.99 Cr (FY 2025) | ₹64.94 Cr | 10.1% | 44.0% | 906 | Bangalore, Karnataka, India |
| Cliantha Research Limited | ₹630.84 Cr (FY 2025) | 2.0% | Ahmedabad, Gujarat, India | |||
| Zoetis Pharmaceutical Research Private Limited | ₹595.44 Cr (FY 2025) | 28.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Aurigene Pharmaceutical Services Limited, buy the company report.
Auditor
Aurigene Pharmaceutical Services Limited is audited by S.R. Batliboi & Associates LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S.R. Batliboi & Associates LLP | FY 2023 | 101049W/E300004 |
Shareholding
The shareholding of Aurigene Pharmaceutical Services Limited is on record for 4 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Aurigene Pharmaceutical Services Limited, buy the company report.
Deals & funding
Aurigene Pharmaceutical Services Limited has 3 deals on record (2 rights issues, 1 debt financing), with disclosed funding of ₹380 Cr; the latest was in May 2024.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| May 2024 | Rights issue | ₹650 Cr | Investors: Aurigene Discovery Technologies Limited |
| Jun 2020 | Debt financing | ₹380 Cr | Investors: DBS Bank Limited |
| Jun 2020 | Rights issue | ₹40 Cr | Investors: Aurigene Discovery Technologies Limited |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Aurigene Pharmaceutical Services Limited has 1 court case on record: 1 filed by Aurigene Pharmaceutical Services. All case is pending.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 1 | 0 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Karnataka | Writ petition | Filed by the company against The Assistant Commissioner of Commercial Tax | Pending |
To see the full case history of Aurigene Pharmaceutical Services Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Aurigene Pharmaceutical Services Limited was last rated by Icra on 29 Jul 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Icra | 29 Jul 2021 |
To see the full credit ratings and regulatory alerts of Aurigene Pharmaceutical Services Limited, buy the company report.
MSME payment delays
Aurigene Pharmaceutical Services Limited has 6 MSME Form 1 returns on record between 2020 and 2023, listing 8 overdue payments to 2 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (2 of 2)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Ina Pharmaceuticals Private Limited | |||
| Prodev Pharma (OPC) Private Limited |
To see the full MSME payment records of Aurigene Pharmaceutical Services Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Aurigene Pharmaceutical Services Limited has a workforce of 906 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.
GST
Aurigene Pharmaceutical Services has 2 GST registrations: 2 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 29AASCA7299J1ZM | Karnataka | Active | 09 Jan 2020 |
| 36AASCA7299J1ZR | Telangana | Active | 01 Jan 2020 |
To see the full GST registrations and return filing status of Aurigene Pharmaceutical Services Limited, buy the company report.
Recent activity
Aurigene Pharmaceutical Services Limited has 12 board changes on record since 2019: 9 appointments and 3 cessations. The latest: Sapna was appointed as Company Secretary on 14 Nov 2024.
3 earlier events are in the company report.
News
Frequently asked questions
Aurigene Pharmaceutical Services is an active public limited company based in Bangalore, Karnataka, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 16 September 2019 (7+ years old) and is registered under CIN U74999KA2019PLC127964.
Aurigene Pharmaceutical Services has 6 current directors and KMP:
- Erez Israeli - Director
- Deepak Sapra - Director
- Mannam Venkata Narasimham - Director
- Jesal Agarwal - Director
- Atul Sachdeva - Cfo
- Sapna - Company Secretary
The latest financial statements of Aurigene Pharmaceutical Services on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 16 July 2025. Year-wise statements from FY 2020 are in the company report.
The GSTIN of Aurigene Pharmaceutical Services is 29AASCA7299J1ZM, registered in Karnataka. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 36AASCA7299J1ZR (Telangana).
The CIN (Corporate Identification Number) of Aurigene Pharmaceutical Services is U74999KA2019PLC127964. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Aurigene Pharmaceutical Services has 1 court case on record: 1 filed by the company. 1 is pending.
Aurigene Pharmaceutical Services was incorporated on 16 September 2019, making it 7+ years old. It is registered with the Registrar of Companies, Bangalore.
Aurigene Pharmaceutical Services has 3 deals on record (2 rights issues, 1 debt financing), with disclosed funding of ₹380 Cr; the latest was in May 2024.
The peers of Aurigene Pharmaceutical Services by revenue are Lambda Therapeutic Research Limited, Icon Clinical Research India Private Limited, Cliantha Research Limited, Zoetis Pharmaceutical Research Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).
Sapna was appointed as Company Secretary on 14 Nov 2024. Jesal Agarwal was appointed as Director on 29 Mar 2024. Ranjana Bhubneswar Pathak ceased to be Director on 12 Jan 2024. Aurigene Pharmaceutical Services has 12 board changes on record in total.
Aurigene Pharmaceutical Services has 6 MSME Form 1 returns on record between 2020 and 2023, listing 8 overdue payments to 2 micro and small suppliers. The latest return was filed on 08 Dec 2023.
Aurigene Pharmaceutical Services can be reached through the website aurigeneservices.com. Its registered office is in Bangalore, Karnataka, India.